# Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Study · id `cardio:ct-nct01087502` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01087502](<https://clinicaltrials.gov/study/NCT01087502>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01087502

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

## Technical summary

Registry record NCT01087502. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-10-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 241 participants (enrolled count; ClinicalTrials.gov record NCT01087502, source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01087502, source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01087502, source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)
- Completion: Not reported
- Results first posted: 2013-10-17 (ClinicalTrials.gov record NCT01087502, source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Finland; Israel; Japan; New Zealand; Slovakia; Sweden (ClinicalTrials.gov record NCT01087502, source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01087502-2014-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Glimepiride
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Intervention (Drug): Linagliptin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: ce36eea334f073684e77023bd93844142a1ed1f79f17b33e5b140e5e74deb2f8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
